SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Helus Pharma, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Attention centers on Helus Pharmas expected Q4 2026 Phase 3 topline results for HLP003, its investigational add-on treatment for major depressive disorder. Traders are split between optimism that the readout could validate the program and concerns about trial uncertainty, potential dilution, and volatility around the binary catalyst.

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

AbCellera Biologics Inc

Attention centers on ABCL635, AbCelleras antibody candidate for menopausal hot flashes, and its Phase 1/2 data presentation at a menopause conference; traders are looking for added evidence on efficacy, durability and safety after encouraging Phase 2 topline results. Bulls see the data as a potential validation of the companys internal pipeline, while skeptics question whether the presentation adds enough beyond known results and warn that expectations and recent volatility may set up a sell-the-news reaction.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

Renewed, unconfirmed takeover chatter around a possible offer from an unidentified West Coast technology company is dominating discussion, with traders speculating about buyers such as Meta while others caution that no bid has been confirmed. Upcoming earnings and concerns about transaction margins are also in focus, but the takeover speculation is driving much of the debate.

XPeng, Inc. is a global physical AI company, which engages in bringing artificial intelligence into the physical world to reshape future mobility and smart living. It developed a full-stack physical AI architecture spanning Turing AI chips, world foundation models, and integrated software and hardware applications. The firm's product portfolio includes smart EVs, robotaxis, and humanoid robots. The company's sales and services drives continuous technological innovation and fosters an open physical AI ecosystem, making life smarter, safer, and better for users worldwide. XPeng, Inc. was founded by Xiao Peng He, Heng Xia, and Tao He in 2015 and is headquartered in Guangzhou, China.

XPeng Inc - ADR

XPeng is drawing attention amid a steep, prolonged selloff, with traders citing weakness across Chinese EV stocks, concerns about demand, profitability and analyst downgrades. Bulls counter that delivery growth, European expansion and AI-chip and robotics initiatives could support the business, while frustrated holders question whether those developments can improve shareholder returns.

ExxonMobil Holdings Corp. is an international energy and petrochemical company, which creates solutions that improve quality of life and meets society’s evolving needs. The company is headquartered in Spring, TX.

ExxonMobil Holdings Corp.

Exxon Mobil Corp

Exxons rally to record highs is drawing attention amid rising crude prices tied to Middle East supply tensions and anticipation of its upcoming quarterly report, with traders also citing stronger refining margins. The conversation is broadly bullish, though some caution that the stock is extended and that oil-price swings or earnings expectations could reverse the move.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Modernas Phase 3 melanoma-vaccine results with Keytruda showed a 42% reduction in recurrence or death risk, but shares sold off as traders judged the outcome against high expectations after a major run-up. The community is split between viewing the data as strong validation of the cancer-vaccine platform and questioning whether the benefit, individualized manufacturing, and commercialization prospects justify the valuation.

Whirlpool Corp. engages in the manufacturing and marketing of home appliances. Its products include home laundry appliances, refrigerators and freezers, cooking appliances, home dishwashers, and room air-conditioning equipment, mixers, and portable household appliances. The firm's brands include Whirlpool, KitchenAid, Maytag, Consul, Brastemp, Amana, Bauknecht, JennAir, and Indesit. It operates through the following geographical segments: Major Domestic Appliances (MDA) North America, Major Domestic Appliances (MDA) Latin America, Small Domestic Appliances (SDA) Global, and Others. The company was founded by Emory Upton, Fred Upton, and Louis C. Upton on November 11, 1911 and is headquartered in Benton Harbor, MI.

Whirlpool Corp.

Whirlpools weak quarterly results, sharply reduced full-year outlook and suspended dividend are driving attention, alongside managements warning of recession-level appliance demand and its attribution of the downturn partly to the Iran war. Traders are debating whether the selloff reflects severe financial and management problems or an overreaction that could create a contrarian buying opportunity; no article was provided that directly supports the catalyst.

Vanguard Index Funds - Vanguard S&P 500 ETF

Vanguard S&P 500 ETF

VOO is drawing attention amid concern about a broad-market pullback, with traders citing rising Treasury yields, persistent inflation and possible Fed rate hikes, alongside geopolitical and energy-market risks. The community is split between recession and crash warnings and investors viewing any dip as a buying opportunity or continuing to favor long-term index investing.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoins sharp weekend selloff and break below a widely watched support level dominate discussion, with traders focused on whether further technical support will hold and pointing to leveraged long liquidations and thin weekend trading. Bearish calls for more downside compete with dip-buying and bear-trap arguments, while some traders blame manipulation without clear evidence.

Celestica, Inc. engages in the provision of supply chain solutions globally to equipment manufacturers and service providers. It operates through the Advanced Technology Solutions (ATS) and Connectivity and Cloud Solutions (CCS) segments. The ATS segment includes aerospace and defense, industrial, smart energy, health tech, and capital equipment businesses. The CCS segment consists of enterprise communications, telecommunications, servers, and storage businesses. The company was founded in 1994 and is headquartered in Toronto, Canada.

Celestica, Inc. - Ordinary Shares (Subordinate Voting)

Celestica, Inc.

Celestica is drawing attention ahead of its earnings report and investor day, with traders also watching hyperscaler results for clues about AI infrastructure demand. The community is divided between expecting strong results and continued growth, and worrying that the broader AI-stock selloff and valuation reset could outweigh solid company fundamentals.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Small-Cap ETFs Beat S&P 500 in 2026: Can the Rally Last?

Small-cap ETFs are beating the S&P 500 in 2026. Will the rally continue? Here's what valuations, earnings and macro trends say.

MLTX Stock Clocks Best Day In Over 6 Months — What’s Driving The Investor Optimism? 

Equity

Clear Street described sonelokimab’s profile in hidradenitis suppurativa as highly competitive and one that readily supports “blockbuster potential.”


MLTX Stock Moves Higher As Traders Position For Late-Stage Trial Catalysts

Moonlake’s lead drug Sonelokimab is being tested across inflammatory conditions, with the biggest near-term focus on hidradenitis suppurativa. 

ONDS Stock Rises Following Acquisition Of Israel-Based Sentry CS

Ondas expects the transaction to close in November 2025, and the terms of the deal have not been disclosed.


Time to fade momentum trade, Jefferies says

Investing.com -- The momentum factor weakened in December, but more downside can be expected in the first quarter, according to a Jefferies strategist.

Aquestive Therapeutics Pushes Retail Sentiment Into ‘Extremely Bullish’ Zone On OAS Drug Trial Success

This study marks the final supportive adult trial in the Anaphylm development program ahead of discussions with the U.S. FDA.

Invesco Exchange-Traded Fund Trust II - Invesco Dorsey Wright SmallCap Momentum ETF

Neutral Sentiment

<ul class="summary-bullets"><li>The comments followed MoonLake’s release of final Week 52 results from its two pivotal late-stage trials in adults with moderate-to-severe hidradenitis suppurativa.</li><li>MoonLake plans to submit its approval application to the FDA by the end of September.&nbsp;</li><li>Retail investors are now awaiting the data from the company’s trials in psoriatic arthritis.</li></ul> Shares of MoonLake Immunotherapeutics (MLTX) surged 15% on Monday, fueled by strong investor reaction to one-year clinical data on sonelokimab for hidradenitis suppurativa and a bullish note from Clear Street.The stock clocked its best day since early January.<h2 class="st-heading-2">Clear Street Sees ‘Blockbuster Potential’ For MoonLake Drug</h2>Clear Street described the drug’s profile in the skin condition as highly competitive and one that readily supports “blockbuster potential.” The firm kept its ‘Buy’ rating and $70 price target, noting the biologics license application remains on track for a September 30 filing and that management still sees priority review from the U.S. Food and Drug Administration as possible.The comments followed MoonLake’s release of final Week 52 results from its two pivotal late-stage trials in adults with moderate-to-severe hidradenitis suppurativa. Hidradenitis suppurativa is a chronic, painful inflammatory skin condition that causes recurring boils, abscesses, and tunneling wounds, mainly in the armpits, groin, and other skin folds.<h2 class="st-heading-2">MLTX Trial Outcome</h2>Roughly two-thirds of patients in the trials achieved at least a 75% reduction in painful abscesses and nodules without worsening elsewhere, while about one-third reached complete clearance of those lesions, MoonLake said. Around one-quarter hit full inflammatory remission. The outcomes improved further from earlier readouts and compared favorably with results seen for competing treatments at similar time points. Patients also reported meaningful gains in quality of life and pain relief.Safety stayed consistent and favorable through one year, with no new issues. Most patients opted to continue in an open-label extension, and early data from adolescents looked encouraging as well, the company said.MoonLake plans to submit its approval application by the end of September, including data from both adults and teens.<h2 class="st-heading-2">How Did MLTX Retail Traders React?</h2>On Stocktwits, retail sentiment around MLTX stock jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.A Stocktwits user expressed optimism for the company’s market capitalization rising as much as $5 billion by year's end, following the submission of an application to the FDA and a priority review. The company currently has a market cap of about $1.63 billion<stembedurl>https://www.stocktwits.com/IronManResurrection/message/657099192</stembedurl>Another user highlighted the company’s other near-term catalysts, including data from two late-stage studies of sonelokimab in psoriatic arthritis. The primary results from the two trials are expected in mid-2026 and in the second half of 2026, respectively.<stembedurl>https://www.stocktwits.com/thezat/message/657088197</stembedurl>According to data from Koyfin, 11 of the 15 analysts covering MLTX rate it ‘Buy’ or higher, while two rate it ‘Hold’ and two ‘Sell.’ The stock has a 12-month average price target of $27.62, which represents a potential upside of about 25% from the stock’s last close.<a href="https://stocktwits.com/symbol/MLTX">MLTX stock</a> has gained 84% this year.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/entx-stock-on-track-for-best-day-in-over-5-years-whats-driving-rally/cZKM5L5R79E">ENTX Stock On Track For Best Day In Over 5 Years — What’s Driving The Rally?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a MoonLake Immunotherapeutics company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Clear Street described sonelokimab’s profile in hidradenitis suppurativa as highly competitive and one that readily supports “blockbuster potential.”

Invesco Dorsey Wright SmallCap Momentum ETF

MoonLake Immunotherapeutics

Vanguard Health Care ETF

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Feed

News

Sentiment

Fundamentals

Info

DWAS Invesco Dorsey Wright SmallCap Momentum ETF

Fundamentals

Latest DWAS News